Yasuhiro Koh

4.8k total citations
131 papers, 3.3k citations indexed

About

Yasuhiro Koh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yasuhiro Koh has authored 131 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 80 papers in Pulmonary and Respiratory Medicine and 43 papers in Cancer Research. Recurrent topics in Yasuhiro Koh's work include Lung Cancer Treatments and Mutations (70 papers), Cancer Genomics and Diagnostics (37 papers) and Lung Cancer Research Studies (25 papers). Yasuhiro Koh is often cited by papers focused on Lung Cancer Treatments and Mutations (70 papers), Cancer Genomics and Diagnostics (37 papers) and Lung Cancer Research Studies (25 papers). Yasuhiro Koh collaborates with scholars based in Japan, United States and United Kingdom. Yasuhiro Koh's co-authors include Nobuyuki Yamamoto, Toshiaki Takahashi, Masakuni Serizawa, Hiroaki Akamatsu, Carlos L. Arteaga, Masahiro Endo, Atsushi Hayata, Nahomi Tokudome, Nagahiro Saijo and Masanori Nakanishi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yasuhiro Koh

123 papers receiving 3.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Yasuhiro Koh	2.0k	1.4k	1.1k	801	278	131	3.3k
Kim Monkhorst	1.8k 0.9×	1.5k 1.1×	986 0.9×	665 0.8×	183 0.7×	112	3.4k
Toru Mukohara	2.3k 1.2×	1.7k 1.2×	1.7k 1.5×	577 0.7×	436 1.6×	128	4.1k
Chunxia Su	2.6k 1.3×	2.3k 1.7×	1.3k 1.2×	996 1.2×	328 1.2×	181	4.5k
Stefania Bartolini	1.8k 0.9×	2.0k 1.5×	1.1k 0.9×	644 0.8×	156 0.6×	104	3.8k
J. M. Nesland	1.5k 0.7×	780 0.6×	1.1k 1.0×	945 1.2×	306 1.1×	59	3.0k
Emiliano Cocco	1.6k 0.8×	833 0.6×	1.1k 1.0×	532 0.7×	130 0.5×	83	3.2k
Ingeborg Tinhofer	1.4k 0.7×	629 0.5×	872 0.8×	848 1.1×	331 1.2×	77	2.5k
Alison Backen	1.5k 0.8×	573 0.4×	713 0.6×	867 1.1×	275 1.0×	41	2.4k
Jasgit C. Sachdev	1.6k 0.8×	558 0.4×	1.7k 1.5×	947 1.2×	285 1.0×	126	3.4k
Gordana Vlahovic	2.2k 1.1×	956 0.7×	920 0.8×	454 0.6×	249 0.9×	93	3.9k

Countries citing papers authored by Yasuhiro Koh

Since Specialization

Citations

This map shows the geographic impact of Yasuhiro Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuhiro Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuhiro Koh more than expected).

Fields of papers citing papers by Yasuhiro Koh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuhiro Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuhiro Koh. The network helps show where Yasuhiro Koh may publish in the future.

Co-authorship network of co-authors of Yasuhiro Koh

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuhiro Koh. A scholar is included among the top collaborators of Yasuhiro Koh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuhiro Koh. Yasuhiro Koh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Tamiya, Akihiro, Daijiro Harada, Shun‐ichi Isa, et al.. (2024). Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer. Lung Cancer. 195. 107917–107917. 4 indexed citations

Ozawa, Yuichi, Yasuhiro Koh, Ryota Shibaki, et al.. (2024). Uncovering the role of tumor cGAS expression in predicting response to PD-1/L1 inhibitors in non-small cell lung cancer. Cancer Immunology Immunotherapy. 74(1). 7–7. 4 indexed citations

Taniguchi, Yoshihiko, Daijiro Harada, Shun‐ichi Isa, et al.. (2024). Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status. BMC Pulmonary Medicine. 24(1). 407–407.

Akamatsu, Hiroaki, Shunsuke Teraoka, Masanori Tanaka, et al.. (2023). A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients. Journal of Pain and Symptom Management. 67(3). 204–211.e1. 3 indexed citations

Miura, Satoru, Yasuhiro Koh, Koichi Azuma, et al.. (2023). Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial. BMC Cancer. 23(1). 6–6. 5 indexed citations

Shibaki, Ryota, Daichi Fujimoto, Takayuki Nozawa, et al.. (2023). P2.13-04 Pathological Images Machine Learning Predicts Long Term Effects for Immunotherapy in Small-Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S368–S368. 1 indexed citations

Akamatsu, Hiroaki, Shunsuke Teraoka, Shinkichi Takamori, et al.. (2022). Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research. 28(15). 3207–3213. 22 indexed citations

Sawa, Kenji, Jun Oyanagi, Mitsuru Fukui, et al.. (2021). Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology. 14(7). 101102–101102. 11 indexed citations

10.

Watanabe, Masaru, Hirotsugu Kenmotsu, Ryo Ko, et al.. (2018). Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Science. 109(8). 2539–2548. 32 indexed citations

11.

Akamatsu, Hiroaki, Yasuhiro Koh, Yuichi Ozawa, et al.. (2018). Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer. 19(6). e871–e874. 12 indexed citations

12.

Akamatsu, Hiroaki, Shunsuke Teraoka, Yasuhiro Koh, et al.. (2018). A Phase II Study of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clinical Lung Cancer. 20(2). 139–141. 5 indexed citations

13.

Tokudome, Nahomi, Hiroki Ueda, Masanori Nakanishi, et al.. (2016). Detection and management of everolimus associated pneumonitis with serum markers for interstitial pneumonia. Annals of Oncology. 27. vii101–vii101.

14.

Watanabe, Masaru, Tomoya Kawaguchi, Shun‐ichi Isa, et al.. (2015). Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clinical Cancer Research. 21(15). 3552–3560. 182 indexed citations

15.

Serizawa, Masakuni, Toshiaki Takahashi, Nobuyuki Yamamoto, & Yasuhiro Koh. (2013). Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells. Journal of Thoracic Oncology. 8(3). 259–269. 41 indexed citations

16.

Kaira, Kyoichi, Masakuni Serizawa, Yasuhiro Koh, et al.. (2011). Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors. Journal of Thoracic Oncology. 6(3). 606–613. 13 indexed citations

17.

Ueda, Yukiko, Shizhen Wang, Nancy Dumont, et al.. (2004). Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility. Journal of Biological Chemistry. 279(23). 24505–24513. 125 indexed citations

18.

Taguchi, Fumiko, Yasuhiro Koh, Fumiaki Koizumi, et al.. (2004). Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)‐sensitive and resistant xenograft models. Cancer Science. 95(12). 984–989. 52 indexed citations

19.

Koizumi, Fumiaki, Fumihiko Kanzawa, Yutaka Ueda, et al.. (2003). Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells. International Journal of Cancer. 108(3). 464–472. 97 indexed citations

20.

Nakamura, Takashi, Fumiaki Koizumi, Noboru Kaneko, et al.. (2001). Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519. Japanese Journal of Cancer Research. 92(6). 597–602. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact